Monograph Details
|
|
Endocrine System
> Diabetes
|
|
NOVOLIN N |
| Manufacturer |
|
Novo Nordisk |
| Legal Classification |
|
OTC |
| Generic Name |
|
Insulin isophane suspension (recombinant) 100Units/mL; inj. |
| Also |
• NOVOLIN 70/30
• NOVOLIN R
|
| Indications |
|
Diabetes. |
| Adults and Children |
|
SC injection only. Onset approx 1.5 hrs, peak 4–12 hrs, duration approx 24 hrs. |
| Precautions |
|
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. |
| Interactions |
|
Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol. |
| Adverse Reactions |
|
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema. |
| How Supplied |
Vials (10mL)—1
PenFill (3mL cartridges)—1
NovoPen 3 (inj device, uses PenFill cartridges)—1
NovoPen Junior (inj device, uses PenFill cartridges)—1
InnoLet (inj device)—5 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
